Thoughts on TCM Syndrome Differentiation and Treatment in Monoclonal Gammopathy of Renal Significance Click Copy

Thoughts on TCM Syndrome Differentiation and Treatment in Monoclonal Gammopathy of Renal Significance


[1] LEUNG N, BRIDOUX F, BATUMAN V, et al. The evaluation of monoclonal gammopathy of renal significance:a consensus report of the International Kidney and Monoclonal Gammopathy Research Group[J]. Nat Rev Nephrol,2019,15(1):45-59.

[2] CIOCCHINI M, ARBELBIDE J, MUSSO C G. Monoclonal gammopathy of renal significance (MGRS):the characteristics and significance of a new meta-entity[J]. Int Urol Nephrol,2017,49(12):2171-2175.

[3] 马哲河,龚淑芳.中西医结合治疗恶性淋巴瘤40例[J].中国中医药信息杂志,2003,10(1):54-55.

[4] 郭志勇,董睿.骨髓瘤肾病的中西医结合治疗[J].中华肾病研究电子杂志,2015,4(2):78-81.

[5] MUNSHI N C. Monoclonal gammopathy of undetermined significance:genetic vs environmental etiologies[J]. Mayo Clin Proc,2007, 82(12):1457-1459.

[6] TAINO G, BORDINI L, SARTO C, et al. [Monoclonal gammopathy of uncertain significance (MGUS) and occupational risk factors:criteria to carry out the health surveillance][J]. G Ital Med Lav Ergon,2019,41(3):202-207.

[7] MAHMOOD U, ISBEL N, MOLLEE P, et al. Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome[J]. Nephrology (Carlton),2017,22(Suppl 1):15-17.

[8] 何娅玲,刘松山,车虹.浅谈中医对多发性骨髓瘤的认识[J].世界最新医学信息文摘,2019,19(20):237-243.

[9] 戴媺,陈志雄.补肾法在血液病中的临床应用[J].医药论坛杂志, 2007,28(10):121-122.

[10] TERRIER B, KARRAS A, KAHN J E, et al. The spectrum of type I cryoglobulinemia vasculitis:new insights based on 64 cases[J]. Medicine (Baltimore),2013,92(2):61-68.

[11] BHUTANI G, NASR S H, SAID S M, et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits[J]. Mayo Clin Proc,2015,90(5):587-596.

[12] RAVINDRAN A, GO R S, FERVENZA F C, et al. Thrombotic microangiopathy associated with monoclonal gammopathy[J]. Kidney Int,2017,91(3):691-698.

[13] LEUNG N, NASR S H. A patient with abnormal kidney function and a monoclonal light chain in the urine[J]. Clin J Am Soc Nephrol, 2016,11(6):1073-1082.

[14] KHERA A, PANITSAS F, DJEBBARI F, et al. Long term outcomes in monoclonal gammopathy of renal significance[J]. Br J Haematol, 2019,186(5):706-716.

[15] KOO E H, SHIN J H, JANG H R, et al. Diagnostic performances of M-protein tests according to the clinical presentations of kidney disease[J]. Eur J Intern Med,2016,33:88-92.

[16] TU H, MOU L, ZHU L, et al. Acquired Fanconi syndrome secondary to light chain deposition disease associated with monoclonal gammopathy of renal significance:A case report[J]. Medicine (Baltimore),2018,97(36):e12027.

[17] SETHI S, RAJKUMAR S V, D’AGATI V D. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases[J]. J Am Soc Nephrol,2018,29(7):1810-1823.

[18] KOUSIOS A, DUNCAN N, TAM F, et al. Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID):diagnostic and treatment challenges for the nephrologist![J]. Kidney Int,2019,95(2):467-468.

[19] 马志芳,罗建华,石英,等.陈以平膏方治疗肾小管酸中毒经验介绍 ——附2例病案报道[J].中国中西医结合肾病杂志,2015,16(11):943- 944.

[20] COHEN C, ROYER B, JAVAUGUE V, et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease[J]. Kidney Int, 2015,88(5):1135-1143.

[21] VAN KRUIJSDIJK R, ABRAHAMS A C, NGUYEN T Q, et al. Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions:is it always necessary?:Two case reports and literature review[J]. J Nephrol,2020,33(3):611-617.

[22] YIN Z, YANG J, NING R, et al. Signal pathways, diseases, and functions associated with the miR-19a/92a cluster and the use of berberine to modulate the expression of this cluster in multiple myeloma cells[J]. J Biochem Mol Toxicol,2018,32(6):e22057.

[23] SHI L, WU Y, LV D L, et al. Scutellarein selectively targets multiple myeloma cells by increasing mitochondrial superoxide production and activating intrinsic apoptosis pathway[J]. Biomed Pharmacother,2019,109:2109-2118.

[24] YANG X J, XI Y M, LI Z J. Icaritin:A novel natural candidate for hematological malignancies therapy[J]. Biomed Res Int, 2019,2019:4860268.

[25] 饶向荣.具有肾脏意义的单克隆免疫球蛋白血症的诊治[J].中华肾病研究电子杂志,2017,6(5):208-213.

[26] LEE H, DUGGAN P, NERI P, et al. Bortezomib maintenance for the treatment of monoclonal gammopathy of renal significance[J]. Mediterr J Hematol Infect Dis,2019,11(1):e2019007.

[27] HOGAN J J, WEISS B M. Bridging the divide:An onco-nephrologic approach to the monoclonal gammopathies of renal significance[J]. Clin J Am Soc Nephrol,2016,11(9):1681-1691.